[1]鲍计章,赵心华,周永明,等.生血灵联合小剂量糖皮质激素治疗激素抵抗型免疫性血小板减少症53例[J].西部中医药,2018,31(02):5-8.
　BAO Jizhang,ZHAO Xinhua,ZHOU Yongming,et al.ShengXueLing Jointed with low-dose Glucocorticoid in Treating 53 Cases of Steroid-resistant idiopathic Thrombocytopenic Purpura[J].Western Journal of Traditional Chinese Medicine,2018,31(02):5-8.
点击复制

生血灵联合小剂量糖皮质激素治疗激素抵抗型免疫性血小板减少症53例()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
31
期数:
2018年02期
页码:
5-8
栏目:
出版日期:
2018-02-15

文章信息/Info

Title:
ShengXueLing Jointed with low-dose Glucocorticoid in Treating 53 Cases of Steroid-resistant idiopathic Thrombocytopenic Purpura
文章编号:
1004-6852(2018)02-0005-04
作者:
鲍计章1，赵心华2，周永明1，朱文伟1，孙伟玲1，胡明辉1，王婕1， 陈海琳1，曾庆1，李昌桂1
1 上海中医药大学附属岳阳中西医结合医院血液科，上海 200437； 2 上海中医药大学基础医学院
Author(s):
BAO Jizhang1, ZHAO Xinhua2, ZHOU Yongming1, ZHU Wenwei1, SUN Weiling1, HU Minghui1, WANG Jie1, CHEN Hailin1, ZENG Qing1, LI Changgui1
1 Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China; 2 Basic Medicine School, Shanghai University of Traditional Chinese Medicine
关键词:
血小板减少症; 免疫性; 激素抵抗型; 生血灵; 糖皮质激素; 环孢素; 生存质量
Keywords:
thrombocytopenia;  immune;  steroid-resistant;  ShengXueLing;  glucocorticoid;  ciclosporin;  survival quality
分类号:
R558+.2
文献标志码:
A
摘要:
目的：观察生血灵联合小剂量糖皮质激素治疗激素抵抗型免疫性血小板减少症(ITP)的临床疗效。方法：将106例患者按随机数字表法分为观察组、对照组各53例。2组均给予小剂量激素治疗，观察组同时给予生血灵系列方辨证论治，对照组同时给予环孢素治疗，2组均连续治疗3个月，观察临床疗效及治疗前后患者生存质量的变化情况。结果：总有效率观察组为54.7%，对照组为37.7%，2组比较差异有统计学意义(P＜0.05)。观察组治疗前后生理、心理、社会、环境等维度评分及总评分比较，差异有统计学意义(P＜0.05)。对照组治疗前后心理评分及总评分比较，差异有统计学意义(P＜0.05)；生理、社会、环境等维度评分比较，差异无统计学意义(P＞0.05)。生理、心理、社会、环境等维度评分及总评分治疗后2组组间比较，差异均有统计学意义(P＜0.05)。结论：生血灵系列方联合小剂量糖皮质激素辨证治疗激素抵抗型ITP疗效显著，且有助于改善患者生存质量。
Abstract:
Objective: To observe clinical effects of ShengXueLing combined with low-dose glucocorticoid in treating steroid-resistant idiopathic thrombocytopenic purpura (ITP). Methods: All 106 patients were allocated to theobservation group and the control group according to random number table method, 53 cases each group, they were given low-dose glucocorticoid, the observation group were differentiated and treated with ShengXueLing, the control group with ciclosporin simultaneously, they were treated for three months consecutively, clinical effects and the changes of survival quality of both groups were observed before and after treating. Results: Total effective rate of the observation group was 54.7%, and the control group was 37.7%, and the difference had statistical meaning (P＜0.05).The difference was statistically significant in the comparisons of dimensional scales including physiology, psychology, society and environment, and total scales before and after treating within the observation group (P＜0.05).The difference was statistically significant in the comparisons of psychological scales and total scales before and after treating within the control group(P＜0.05); the difference had no statistical meaning in the comparisons of dimensional scales including physiology, society and environment(P＞0.05), and there was a significant difference in the comparisons of dimensional scales including physiology, psychology, society and environment, and total scales between both groups (P＜0.05). Conclusion: ShengXueLing prescription series combined with low-dose glucoco-rticoid is effective in treating steroid-resistant ITP, and it is helpful to improve survival quality of the patients.

相似文献/References:

[1]王微,魏巍,宋辉,等.中医脏腑辨治联合激素治疗原发免疫性血小板减少症的研究进展[J].西部中医药,2023,36(01):146.[doi:10.12174/j.issn.2096-9600.2023.01.34]
　WANG Wei,WEI Wei,SONG Hui,et al.Research Progress of Visceral Differentiation Joined with Hormone in Treating Primary Immune Thrombocytopenia[J].Western Journal of Traditional Chinese Medicine,2023,36(02):146.[doi:10.12174/j.issn.2096-9600.2023.01.34]
[2]马西虎,黄志惠,吴雪琴,等.慢性原发免疫性血小板减少症中医证候分型的前瞻性研究[J].西部中医药,2023,36(12):46.[doi:10.12174/j.issn.2096-9600.2023.12.11]
　MA Xihu,HUANG Zhihui,WU Xueqin,et al.Prospective Study on TCM Syndrome Types of Chronic Primary Immune Thrombocytopenia[J].Western Journal of Traditional Chinese Medicine,2023,36(02):46.[doi:10.12174/j.issn.2096-9600.2023.12.11]

备注/Memo

备注/Memo:
收稿日期：2017-10-25 *基金项目：国家自然科学基金项目(编号81774258)；第六批全国老中医药专家学术经验继承人项目；上海市科委科技支撑计划中医重点资助项目(编号14401970800);上海中医药大学预算内资助项目(编号2013JW48);上海市杏林新星资助计划(编号ZY3-RCPY-2-2012);上海中医药大学高峰高原学科临床人才专项；周永明上海市名老中医学术经验研究工作室项目(编号SHGZS-2017019)；周永明上海中医药大学名老中医药专家学术经验研究工作室项目(编号SZYMZYGZS4018)。 作者简介：鲍计章(1981—)，男，博士后，美国加州大学欧文分校访问学者，主治医师。研究方向：血液病的临床与实验研究。
更新日期/Last Update: 2018-02-15